Syncromune® Reports Long-Term Data from Phase 1 Study in Metastatic Prostate Cancer with Investigational SYNC-T Therapy SV-102 Posted October 27, 2026
Syncromune® to Present Updated Long-Term Overall Survival Data from Phase 1 Trial of SYNC-T Therapy SV-102 in Metastatic Prostate Cancer at ESMO Congress 2026 Posted October 19, 2026
Syncromune® Presents SYNC-T Therapy: Image-Guided Cryolysis and Intratumoral Immunotherapy at CIRSE 2026 Posted September 10, 2026
Syncromune® Presents Multi-Modal Efficacy Assessment Framework at Inaugural Gustave Roussy Intratumoral Immunotherapy Symposium Posted June 17, 2026
Syncromune®, Inc. Presents Innovative SYNC-T Combination Immunotherapy Approach at Major European Interventional Oncology Conference Posted April 29, 2026
Syncromune Continues to Strengthen Executive and Clinical Leadership with Appointment of Dr. Stephen P. Dale, M.D., as Chief Medical Officer Posted January 6, 2026
Syncromune®, Inc. Presents Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at Society of Urological Oncology 26th Annual Meeting Posted December 4, 2025
Syncromune®, Inc. to Present Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at the Society of Urological Oncology 26th Annual Meeting Posted November 20, 2025
Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program Posted June 16, 2025
Syncromune® Inc. Presents Positive Results from SYNC-T™ Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025 Posted June 2, 2025
